Recent developments include reiteration of full year 2025 financial results, strengthening of the balance sheet, completion of patient enrollment in Phase 2a study of GRI-0621 for IPF with positive interim safety and biomarker results, securing new U.S. patents, and CEO participation in investor events.

• GRI Bio reiterated full year 2025 financial results and reported strengthening of its balance sheet [N1].
• The company secured a new U.S. composition of matter patent covering novel compound structures [N2].
• Patient enrollment was completed in the Phase 2a study of GRI-0621 for idiopathic pulmonary fibrosis, with interim results showing safety and tolerability [N3].
• Positive interim safety results for GRI-0621 in the Phase 2a IPF study were reported [N4].
• CEO Marc Hertz participated in a live webcast fireside chat at A.G.P.'s Annual Healthcare Company Showcase in May 2025 [N5].
• Positive Phase 2a interim safety and biomarker results for GRI-0621 in IPF treatment were reported [N6].
• CEO Marc Hertz discussed advancements in NKT cell modulators for IPF in a recent virtual investor segment [N7].
• The company anticipated key Phase 2a data readouts for GRI-0621 in 2025 while securing cash runway for operations [N8].

GRI Bio's lead candidate GRI-0621 has demonstrated safety and tolerability in Phase 2a trials for IPF, with biomarker and functional data indicating potential anti-fibrotic effects and immune modulation. The company has a growing patent portfolio protecting its novel compounds and a pipeline including GRI-0803 targeting autoimmune diseases. Strong liquidity and recent capital raises support ongoing development activities. Positive clinical data and regulatory engagement could enable advancement to Phase 2b trials and potential conditional approvals, addressing significant unmet medical needs in fibrotic and autoimmune disorders.

GRI Bio is a clinical-stage company with no approved products and a history of net losses, including a $1.6 million loss in Q2 2026. The company faces risks related to clinical trial outcomes, regulatory approvals, and funding availability. Its market value is below Nasdaq's new minimum listing requirement, which if enforced, could lead to trading suspension and delisting, adversely affecting capital raising and investor confidence. The novel mechanism and oral formulation have yet to demonstrate definitive clinical benefit in larger trials. Competition and the inherent risks of drug development in fibrotic and autoimmune diseases add to uncertainty.

GRI Bio's moat is based on its proprietary oral formulation of tazarotene (GRI-0621) targeting iNKT cells, a novel mechanism in treating fibrotic lung diseases such as IPF, where current therapies have limited efficacy and tolerability. The company has secured composition of matter patents in the U.S. and Europe covering its novel compounds, supporting intellectual property protection. Its clinical-stage status with positive Phase 2a safety and biomarker data provides early clinical validation. The specialized focus on immune modulation in fibrotic and autoimmune diseases, combined with a proprietary compound library and patent portfolio, contributes to potential competitive differentiation. However, as a clinical-stage company, the moat is contingent on successful further development and regulatory approvals.

• Nasdaq Listing Compliance Risk: The company’s market value of listed securities is below the new Nasdaq minimum requirement of $5 million, which is currently stayed by the SEC. If the rule becomes effective, failure to meet the requirement for 30 consecutive business days could result in immediate trading suspension and delisting proceedings, impacting liquidity and capital access [Q0][Q1].
• Clinical Development Risk: GRI-0621 is in early clinical development with Phase 2a data available. Future trial outcomes, regulatory feedback, and funding availability will affect the ability to advance development and achieve approvals [S1].
• Financial Risk: The company reported a net loss and negative EPS in Q2 2026, reflecting ongoing expenses without product revenue. Continued capital raises and cash management are critical to sustain operations [S2].
• Regulatory and Market Risk: Approval and commercialization depend on regulatory agency decisions and market acceptance. Novel mechanisms and therapies face uncertainties in clinical efficacy and safety profiles [S1].

• GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies targeting diseases with dysregulated immune responses, including inflammatory, fibrotic, and autoimmune disorders [S1].
• The lead product candidate is GRI-0621, an oral inhibitor of type 1 invariant natural killer T (iNKT) cells, formulated as an oral form of tazarotene, a synthetic retinoid acid receptor-beta and gamma selective agonist [S1].
• GRI-0621 is being developed for severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), a progressive and life-threatening lung disease affecting approximately 140,000 people in the US and an estimated 3 million globally [S1].
• GRI-0621 has been evaluated in a randomized, double-blind, multi-center Phase 2a clinical trial in IPF patients, with 35 patients enrolled and 19 completing treatment in the active arm [S1].
• The Phase 2a trial met its primary endpoint of safety and tolerability after 12 weeks, with no treatment-related serious adverse events reported and common adverse events including dry skin, dry lips, muscle and joint pain [S1].
• Secondary and exploratory endpoints showed biomarker changes suggestive of anti-fibrotic effects, including decreases in fibrosis formation markers and increases in fibrosis resolution markers, as well as improvements in lung injury and repair gene expression [S1].
• Functional lung capacity (FVC) showed placebo-adjusted increases in the GRI-0621 treated arm, with 39% of treated subjects experiencing an increase in FVC at 12 weeks compared to 80% decline in placebo arm [S1].
• GRI-0621 treatment demonstrated immunomodulatory effects consistent with iNKT cell inactivation, including changes in T cell cytokine profiles and reductions in profibrotic cytokines [S1].
• The company plans to use Phase 2a results to inform dose, safety, sample size, and clinical trial design for future trials, including a potential Phase 2b trial subject to FDA clearance and funding [S1].
• GRI Bio's product portfolio also includes GRI-0803, a novel oral agonist of type 2 diverse Natural Killer T cells, intended for autoimmune disorders such as lupus and multiple sclerosis; IND-enabling studies and Phase 1 trials are planned [S1].
• The company has conducted multiple reverse stock splits between 2024 and 2026 to consolidate shares [S1].
• GRI Bio completed securities purchase agreements in 2024 and 2025, raising capital through public offerings and warrant issuances, with Wainwright as placement agent [S1].
• As of June 30, 2026, the company reported cash and cash equivalents of $10.947 million, current assets of $11.334 million, current liabilities of $1.1 million, resulting in a current ratio of 10.3 and a cash ratio of 9.95, indicating strong liquidity [S2].
• The company reported a net loss of $1.643 million and basic and diluted EPS of -$0.91 for the quarter ended June 30, 2026 [S2].
• GRI Bio has secured new U.S. composition of matter patents covering novel compound structures and advanced its global patent strategy with a European patent grant for NKT cell modulator innovation [N2][N1].
• The company completed patient enrollment in the Phase 2a study of GRI-0621 for IPF, with interim results showing safety and tolerability [N3][N4].
• GRI Bio's CEO Marc Hertz has actively communicated company progress and scientific advancements in investor segments and conferences [N5][N7].
• The company has regained compliance with Nasdaq minimum bid price rules as of March 2025 [N8].
• The SEC has approved a new Nasdaq Market Value of Listed Securities (MVLS) requirement of $5 million, which is currently stayed; GRI Bio's MVLS is below $5 million as of the latest filing, posing a potential risk of trading suspension and delisting if the rule becomes effective [Q0][Q1].